Cavalcante Tests Hot For Stanozolol | MMA NEWS

June 18, 2012 5:44 pm by Kinch

By: Jason Kindschy

Another win bites the dust.

The culprit of Rafael “Feijao” Cavalcante’s failed drug test was the anabolic steroid known as Stanozolol. The same drug that fellow Brazilian fighter Christine “Cyborg” Santos failed for in December of 2011.

The California State Athletic Commission announced today that “Feijao” failed for Stanozolol, he will be suspended for 1 year, face a $2,500 fine, and the win over Mike Kyle will be overturned to a no-contest. Cavalcante’s win over Kyle was on the night Strikeforce Heavyweight Grand Final back on May 19th in San Jose, California. The win came by way of guillotine choke, 33 seconds into the first round. This puts Rafael Cavalcante’s record at 11-3-1.

The win over Mike Kyle was allegedly going to put “Feijao” in line to fight Gegard Mousasi (32-3-2) for the vacant Strikeforce light-heavyweight title.

Stanozolol, also known as Winstrol, or Tenabol, derives from dihydrotestosterone, and is a commonly used performance enhancer by athletes of all kinds. All reputable athletic commissions and boards ban it across the globe. Stanozolol has even been used for horse racing in the U.S.

The CSAC says that Cavalcante was tested on May 18th, and CSAC executive officer George Dodd stated. “Anabolic agents and other banned substances put not only the users of those agents at risk, but their opponents as well. The commission simply will not tolerate their use.”

Related Stories:

Cyborg Issues Apology For Failed Drug Test

Feijao Suspended For One Year Following Failed Drug Test

For all the latest MMA and UFC news has got you covered!

Tags: , , , , , , , ,


Shouted out after victory to the UFC masses, BJPENN.COM is the home to multiple time champion BJ Penn. After a decade of on-line operation BJPENN.COM has evolved into the most reliable destination for all your fighter interviews, fighter blogs and MMA/UFC news stories.

Advertise with us

For all advertising inquiries click here.

About us

Please contact us for all website inquiries.